ReShape Lifesciences Inc.
RSLS
$0.6266
-$0.0084-1.32%
| Weiss Ratings | RSLS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Very Weak | |||
| Risk Grade | E+ | |||
| Reward Grade | E | |||
| Rating Factors | RSLS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Fair | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Good | |||
| Total Return Index | Very Weak | |||
| Volatility Index | Very Weak | |||
| Beta / Standard Deviation | RSLS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 1.68 | |||
| Price History | RSLS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -36.71% | |||
| 30-Day Total Return | -83.38% | |||
| 60-Day Total Return | -86.72% | |||
| 90-Day Total Return | -88.91% | |||
| Year to Date Total Return | -86.26% | |||
| 1-Year Total Return | -93.61% | |||
| 2-Year Total Return | -99.65% | |||
| 3-Year Total Return | -99.98% | |||
| 5-Year Total Return | -100.00% | |||
| 52-Week High % Change | -97.81% | |||
| 52-Week Low % Change | 1.44% | |||
| Price | RSLS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $29.00 | |||
| 52-Week Low Price | $0.63 | |||
| 52-Week Low Price (Date) | Mar 13, 2025 | |||
| 52-Week High Price (Date) | May 29, 2024 | |||
| Valuation | RSLS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 2.10M | |||
| Enterprise Value | 1.55M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -18.59 | |||
| Earnings Per Share Growth | -91.23% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 0.04 | |||
| Price/Book (Q) | 0.30 | |||
| Enterprise Value/Revenue (TTM) | 0.19 | |||
| Price | $0.63 | |||
| Enterprise Value/EBITDA (TTM) | -0.20 | |||
| Enterprise Value/EBIT | -0.20 | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | RSLS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 508.90K | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | RSLS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 949 429 6680 | |||
| Address | 18 Technology Drive Irvine, CA 92618 | |||
| Website | www.reshapelifesciences.com | |||
| Country | United States | |||
| Year Founded | 2002 | |||
| Profitability | RSLS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -96.78% | |||
| Profit Margin | -86.36% | |||
| Management Effectiveness | RSLS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -73.65% | |||
| Return on Equity | -- | |||
| Income Statement | RSLS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 8.18M | |||
| Total Revenue (TTM) | 8.18M | |||
| Revenue Per Share | $16.08 | |||
| Gross Profit (TTM) | 5.58M | |||
| EBITDA (TTM) | -7.90M | |||
| EBIT (TTM) | -7.92M | |||
| Net Income (TTM) | -7.07M | |||
| Net Income Avl. to Common (TTM) | -7.07M | |||
| Total Revenue Growth (Q YOY) | 6.36% | |||
| Earnings Growth (Q YOY) | 55.26% | |||
| EPS Diluted (TTM) | -18.59 | |||
| EPS Diluted Growth (Q YOY) | 94.77% | |||
| Balance Sheet | RSLS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 743.00K | |||
| Cash Per Share (Q) | $1.46 | |||
| Total Current Assets (Q) | 5.34M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 1.49M | |||
| Current Ratio (Q) | 1.326 | |||
| Book Value Per Share (Q) | $2.11 | |||
| Total Assets (Q) | 5.62M | |||
| Total Current Liabilities (Q) | 4.03M | |||
| Total Debt (Q) | 191.00K | |||
| Total Liabilities (Q) | 4.13M | |||
| Total Common Equity (Q) | 1.49M | |||
| Cash Flow | RSLS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | 0.00 | |||
| Cash from Financing (TTM) | 5.49M | |||
| Net Change in Cash (TTM) | -706.00K | |||
| Levered Free Cash Flow (TTM) | -3.74M | |||
| Cash from Operations (TTM) | -6.20M | |||
